Doctors are diagnosing more patients as US market normalizes, says Lundbeck CEO

The Covid-19 pandemic has been tough on several of the drugs sold by Lundbeck but the clouds seem to be lifting and recovery might be on the horizon, making Lundbeck ramp up marketing efforts of migraine drug Vyepti.
Photo: Gregers Tycho/ERH
Photo: Gregers Tycho/ERH
by marketwire, translated by daniel pedersen

Lundbeck's newest drugs have been received well, not least on the important US market, on which sales growth of key products appear to have forward momentum.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading